Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mariangela Bruccoleri
Observed name:
M. Bruccoleri
Institution:
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Observed institutions:
University of Milan,
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
ORCID:
0000-0001-7400-4854
Observed ORCID:
0000-0001-7400-4854
OpenAlex ID:
A5055756474
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
2021
·
Valentina Burgio
, Massimo Iavarone
, et al.
·
Cancer Management and Research
·
45
PDF
Prothrombin induced by vitamin K absence or antagonist‐II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C‐related cirrhosis treated with direct‐acting antiviral agents
2021
·
Elisabetta Degasperi
, Riccardo Perbellini
, et al.
·
Alimentary Pharmacology & Therapeutics
·
25
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
2023
·
Massimo Iavarone
, Eleonora Alimenti
, et al.
·
Liver Cancer
·
21
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study
2024
·
Mara Persano
, Andrea Casadei-Gardini
, et al.
·
Oncology
·
17
PDF
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma
2023
·
Catia Giovannini
, Fabrizia Suzzi
, et al.
·
Cancers
·
14
PDF
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma
2023
·
Laura Gramantieri
, Fabrizia Suzzi
, et al.
·
European Journal of Immunology
·
12
PDF
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
2024
·
Mara Persano
, Margherita Rimini
, et al.
·
Targeted Oncology
·
11
The impact of BCLC recommendations on survival for patients with hepatocellular carcinoma
2025
·
Massimo Iavarone
, Eleonora Alimenti
, et al.
·
Hepatology Communications
·
10
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study
2025
·
Alessandro Vitale
, Jung Sun Kim
, et al.
·
Liver Cancer
·
8
PDF
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab
2025
·
Bernardo Stefanini
, Fabio Piscaglia
, et al.
·
Liver Cancer
·
8
PDF
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma
2025
·
L. Gramantieri
, A. Montagner
, et al.
·
ESMO Open
·
6
Long-term outcomes of atezolizumab–bevacizumab in unresectable hepatocellular carcinoma: A real-world study
2026
·
Francesco Tovoli
, Massimo Iavarone
, et al.
·
Hepatology
·
5
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab
2025
·
Andrea Dalbeni
, Filippo Cattazzo
, et al.
·
Scientific Reports
·
5
PDF
Modified Charlson Comorbidity Index to Improve Management of Patients with Hepatocellular Carcinoma: A Step Towards Multiparametric Approach
2026
·
Eleonora Alimenti
, Massimo Iavarone
, et al.
·
Cancers
·
3
PDF
ASAP score predicts early HCC recurrence after complete radiological response to locoregional treatments
2026
·
Lorenzo Canova
, Massimo Iavarone
, et al.
·
Digestive and Liver Disease
·
3
PDF
Comparable 5‐Year Survival in People With and Without HIV Following Hepatocellular Carcinoma Diagnosis: A Multicenter Study
2025
·
Massimo Iavarone
, Eleonora Alimenti
, et al.
·
Liver International
·
2
Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)
2026
·
Andrea Casadei‐Gardini
, Lorenzo Canova
, et al.
·
Liver International
·
1
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes
2026
·
Andrea Dalbeni
, Marco Vicardi
, et al.
·
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
·
1
PDF
Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practice
2024
·
E. Alimenti
, M. Iavarone
, et al.
·
Digestive and Liver Disease
·
1
How field practice complies with BCLC 2022 recommendations for hepatocellular carcinoma management
2023
·
E. Alimenti
, M. Iavarone
, et al.
·
Digestive and Liver Disease
·
1
Baveno VI criteria validation and development of a new non-invasive strategy for varices rule-out in patients with HCC (SAPHE-R: Stiffness, ALBI, Platelets, HEpatocellular carcinoma Rule)
2026
·
Lorenzo Argiento
, Lorenzo Canova
, et al.
·
Hepatology
Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores
2026
·
Bernardo Stefanini
, Lorenza Rimassa
, et al.
·
Liver International
PDF
Comparing ECOG-PS and Charlson Comorbidity Index for stratification of hepatocellular carcinoma prognosis across treatments
2026
·
Simone Famularo
, Flavio Milana
, et al.
·
European Journal of Surgical Oncology
PDF
TOP-375-YI Prognostic impact of neoplastic portal vein thrombosis and extrahepatic metastases in advanced hepatocellular carcinoma receiving Atezolizumab–Bevacizumab: a multicenter real-world study
2026
·
Filippo Cattazzo
, Michele Bevilacqua
, et al.
·
Journal of Hepatology
FRI-381 Inhibition of the renin–angiotensin system does not improve the outcomes of hepatocellular carcinoma treated with atezolizumab–bevacizumab
2026
·
Alfredo Vozza
, Costanza Winchler
, et al.
·
Journal of Hepatology
Show more works
View as search
Works count:
40
Citation count:
199
H-index:
8
I10-index:
8
Year
Topic
Type